Introduction
============

Autism spectrum disorder (ASD) is a neurodevelopmental clinical condition currently diagnosed based on the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria reflecting symptoms, possibly of varying severity, in social interaction, communication and behavior ([@B9]; [@B365]). ASD occurs in 1:68 individuals in the United States ([@B29]) and complex genetic interactions appear responsible for a high degree of heterogeneity of the clinical symptoms in ASD. Individuals with ASD often co-express other comorbidities including epilepsy which often complicates diagnosis and treatment. Alterations in neuronal structures in different brain regions have been reported in ASD individuals, including increased dendritic spine density in cortical pyramidal neurons ([@B271]; [@B575]) as well as stunting of dendritic branching in the hippocampus ([@B492]; [@B40]). In addition, subcortical band heterotopia, representing alterations in cell migration has also been found in a child with ASD ([@B43]). These brain regions are often characterized with neuroanatomical irregularities in ASD ([@B168]). The defective regulation for structural stability of neurons may be one of the underlying mechanisms that contribute to the anatomical changes in ASD.

Autism spectrum disorder is typically diagnosed during the first 3 years of life, a period of extensive neurite formation, synaptogenesis and refinement ([@B272]; [@B688]; [@B555]; [@B387]). Indeed, brain imaging studies from individuals with ASD and anatomical measurements of neuronal structure in post-mortem tissues exhibit differences in neuronal connectivity derived from the disruption of neurite outgrowth, synapse formation and stabilization ([@B492]; [@B271]; [@B463]). Studies of human induced pluripotent stem cells (iPSCs) derived from people with ASD also have identified defects of neuronal structure ([@B233]; [@B424]). Genome-wide association studies on individuals with ASD and their families revealed several risk genes that may be the common molecular targets in autism ([@B76]; [@B219]; [@B270]; [@B440], [@B442]; [@B85], [@B83]; [@B520]; [@B540]; [@B555]; [@B676]; [@B13]; [@B72]; [@B142]; [@B153]; [@B279]; [@B387]; [@B473]; [@B500]; [@B587]; [@B677]). Animal studies of these genes further identify several specific cellular pathways during brain development that are vulnerable in ASD, including the disruption of neurite outgrowth, dendritic spine formation, and synaptic function (**Figure [1](#F1){ref-type="fig"}**) ([@B630]; [@B68]; [@B270]; [@B463]; [@B688]; [@B175]; [@B555]; [@B54]; [@B153]; [@B473]; [@B470]). Differences in environment as well as the presence of multiple gene mutations occurring in the same individual with autism complicate studies of the relationship between each gene and the phenotype observed. However, because similar cellular pathways (e.g., neurite outgrowth) are altered in different affected individuals, we can potentially develop therapeutic interventions to help mitigate the autism phenotypes.

![**Diagram of autism-risk genes implicated in regulating the structural stability of neurons.** Each circle represents a cellular pathway to regulate the structural stability of neurons, including neurite outgrowth (red), dendritic spine or synapse formation (blue), and synaptic plasticity (gold). Experimental evidence shows that many autism-risk genes regulate at least one cellular pathway to maintain the integrity of neuronal structures. Genes that regulate only one pathway are labeled in light gray. Genes that regulate two pathways are labeled in dark gray. Genes that regulate three pathways are labeled in black. The summaries of autism-risk genes that affect each cellular pathway can be found in **Tables [1](#T1){ref-type="table"}**--**[3](#T3){ref-type="table"}**.](fncel-10-00263-g001){#F1}

During development, neurite outgrowth and synapse formation are dynamic processes and their maturation is mutually dependent on proper guidance. Neurites initially exhibit frequent branch additions and retractions. Once dendrite arbors are established, productive synapse formation later in life and the accompanying activation of post-synaptic signaling machinery promotes arbor stability ([@B147]; [@B652]; [@B490]; [@B651]; [@B122]; [@B429]). Conversely, a loss of synaptic inputs leads to dendritic loss ([@B294]; [@B382]; [@B127]; [@B534]). This reciprocal regulation contributes to the refinement of dendrites and synapses as the neurons mature ([@B653]; [@B589]; [@B258]; [@B320]). Thus, maintaining the structural stability of neurons and synapses is critical for proper brain function. Alterations in these processes likely underlie the disruption of normal dendrite and dendritic spine structure in neurological disorders, including neurodevelopmental conditions, psychiatric disorders, and neurodegenerative diseases ([@B190]; [@B357] [@B357]; [@B463]; [@B328]; [@B688]; [@B320]; [@B54]).

It is well-accepted that ASD is not a monogenetic disorder, instead, it is often a neurological condition resulted from multiple mutations of several different genes. Although knockout, knockin, or transgenic approaches of autism-risk genes in animal models have demonstrated some of the autistic-like behaviors ([@B301]), the limitation of the number of genes being manipulated in animals makes it difficult to recapitulate the human condition experimentally. Furthermore, ASD is a common comorbid condition in individuals with other neurodevelopmental disorders. The similar representation of the symptoms but different contribution of genetic mutations often complicates the diagnosis and the treatment. The complex profile of gene mutations makes it difficult to call a gene "the autism gene." However, the list of autism-risk genes provides us a direction to understand the potentially vulnerable pathways in neurons that may be therapeutic targets to develop more efficient interventions for ASD. Indeed, in addition to the structural stability of neurons, several cellular pathways including transcriptional regulation ([@B153]; [@B517]), excitatory/inhibitory (E/I) balance ([@B60]; [@B269]; [@B505]; [@B206]; [@B421]), cerebellar development ([@B640]; [@B239]), and autoregulatory feedback loops ([@B406]) have been proposed to be vulnerable in autism. In this review, we focus on recent identified autism-risk genes that have been shown to regulate neuronal structures and circuit formation, including aspects of neurite outgrowth (**Table [1](#T1){ref-type="table"}**), synapse formation and spine stability (**Table [2](#T2){ref-type="table"}**), and synaptic plasticity (**Table [3](#T3){ref-type="table"}**). We will discuss the known biological function of those individual autism-risk genes in neurons and how they converge into common pathways. We have categorized these genes into cytoskeletal regulators, adhesion molecules, cell surface receptors, signaling molecules, as well as synaptic proteins (**Figure [2](#F2){ref-type="fig"}**). In addition, we include genes causing syndromic disorders in the discussion to highlight the importance of maintaining the neuronal structures for proper brain function.

###### 

Summary of autism-associated genes that regulate neurite outgrowth.

  Functional category                   Gene         Representative references
  ------------------------------------- ------------ ---------------------------------------------------------------------------------------------------------
  **Cytoskeletal regulator**                         
                                        *MYO16*      [@B456]; [@B670]
                                        *CTTNBP2*    [@B542]
                                        *ELMO1*      [@B194]; [@B332]
  **Adhesion molecule**                              
                                        *CDHs*       [@B179]; [@B44]; [@B574]; [@B197]
                                        *PCDH*       [@B596]; [@B404]; [@B302]
                                        *NRXN*       [@B218]
                                        *NLGN*       [@B218]
                                        *CNTNAP2*    [@B14]
                                        *CNTN*       [@B666]
                                        *NCAM2*      [@B536]
  **Surface receptor**                               
                                        *GRIN2B*     [@B184]; [@B180]; [@B532]; [@B80]
                                        *NTRK*       [@B295]
  **Signaling molecule**                             
                                        *DYRK1A*     [@B238]; [@B47]; [@B220]; [@B341]
                                        *CDKL5*      [@B106]; [@B8]; [@B200]
                                        *PTEN*       [@B286]; [@B329]; [@B685]
  **Synaptic protein**                               
                                        *STXBP5*     [@B512]
                                        *PRICKLE1*   [@B358]
  **Syndromic disorder related gene**                
                                        *FMR1*       [@B204]; [@B17]; [@B594]; [@B53]; [@B11]
                                        *MECP2*      [@B202]; [@B296]; [@B686]; [@B32]; [@B45]; [@B315]; [@B126]; [@B379]; [@B426]; [@B559]; [@B288]; [@B30]
                                        *UBE3A*      [@B166]; [@B394]; [@B601]
                                        *TSC1/2*     [@B191]; [@B116]
                                                     

###### 

Summary of autism-associated genes that regulate synapse/spine formation.

  Functional category                   Gene        Representative references
  ------------------------------------- ----------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cytoskeletal regulator**                        
                                        *ADNP*      [@B446]
                                        *CTTNBP2*   [@B108]; [@B107]; [@B262]
                                        *SYNGAP1*   [@B103]; [@B325]; [@B435]; [@B506]; [@B120]; [@B1]
                                        *ELMO1*     [@B311]
  **Adhesion molecule**                             
                                        *CDHs*      [@B50]; [@B268]; [@B69]; [@B585]; [@B454]; [@B561]; [@B44]; [@B646]; [@B197]
                                        *PCDH*      [@B591]
                                        *NRXN*      [@B155]; [@B318]; [@B222]
                                        *NLGN*      [@B527]; [@B482]; [@B113]; [@B346]; [@B615]; [@B330];
                                        *CNTNAP2*   [@B14]; [@B212]; [@B613]
                                        *CNTN*      [@B347]; [@B569]; [@B514], [@B513]; [@B588]
  **Surface receptor**                              
                                        *GRIN2B*    [@B2]; [@B180]; [@B73]; [@B436]; [@B304]
                                        *GRIK2/4*   [@B264]; [@B331]
                                        *NTRK*      [@B393]
  **Signaling molecule**                            
                                        *DYRK1A*    [@B47]; [@B455]; [@B582]
                                        *CDKL5*     [@B687]; [@B159]
                                        *PTEN*      [@B329]; [@B195]; [@B366]; [@B485]; [@B681]; [@B243]; [@B144]
  **Synaptic protein**                              
                                        *SHANK3*    [@B515]; [@B504]; [@B267]; [@B458]; [@B622]; [@B635]; [@B459]
                                        *DLGAP2*    [@B291]
  **Syndromic disorder related gene**               
                                        *FMR1*      [@B131]; [@B642]; [@B71]; [@B282]; [@B430]; [@B530]; [@B205]; [@B319]; [@B388]; [@B17]; [@B229], [@B228]; [@B163]; [@B141]; [@B452]; [@B344]; [@B486]; [@B53]; [@B248]; [@B11]; [@B645]
                                        *MECP2*     [@B202]; [@B686]; [@B97]; [@B426]; [@B559]; [@B288]; [@B30]
                                        *UBE3A*     [@B166]; [@B225]; [@B667]; [@B308]; [@B601]
                                        *TSC1/2*    [@B581]
                                                    

###### 

Summary of autism-associated genes that regulate synaptic plasticity.

  Functional category                   Gene        Representative references
  ------------------------------------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cytoskeletal regulator**                        
                                        *SYNGAP1*   [@B618]; [@B506]; [@B89]; [@B120], [@B121]; [@B448]
  **Adhesion molecule**                             
                                        *CDHs*      [@B69]; [@B371]; [@B585]; [@B70]; [@B392]
                                        *NRXN*      [@B346]; [@B182]
                                        *NLGN*      [@B113]; [@B615]; [@B118]; [@B566]
  **Surface receptor**                              
                                        *GRIN2B*    [@B73]; [@B436]; [@B634]; [@B662]; [@B509]; [@B173]
                                        *GRIK2/4*   [@B134]; [@B264]; [@B673]; [@B331]; [@B6]
  **Signaling molecule**                            
                                        *CDKL5*     [@B159]
                                        *PTEN*      [@B195]; [@B366]
  **Synaptic protein**                              
                                        *SHANK3*    [@B33]; [@B458]; [@B635]; [@B459]
                                        *DLGAP2*    [@B291]
                                        *STXBP5*    [@B34]; [@B49]
  **Syndromic disorder related gene**               
                                        *FMR1*      [@B530]; [@B319]; [@B78]; [@B24]
                                        *MECP2*     [@B130]; [@B148]; [@B22]; [@B403]; [@B96]; [@B680]; [@B126]; [@B348]; [@B432]; [@B58]; [@B408]; [@B487]; [@B684]; [@B409]; [@B158]; [@B160]; [@B151]
                                        *UBE3A*     [@B665]; [@B523]; [@B550]; [@B246]
                                                    

![**Schematic illustration of how autism-risk genes regulate neuronal structure and their sites of action.** An illustration of a dendritic segment containing a dendrite and a dendritic spine is enlarged from the box region on the left and shown on the right. Microtubules (green) and actin filaments (blue) are two major cytoskeletons found in dendrites and dendritic spines, respectively. Autism-risk genes (in bold font) are categorized by their main function and color coded accordingly. (1) Cytoskeletal proteins (gray rounded rectangular box): MYO16, CTTNBP2, and ADNP, directly regulate actin and microtubule function to control dendritic spine and neurite stability. ELMO1 and SYNGAP1 regulate actin dynamics to control spine stability via small RhoGTPases. (2) Adhesion molecules (colored rectangular box): Cadherins (CDHs), protocadherins (PCDHs), and neurexin (NRXN)-neuroligin (NLGN) complex, as well as surface receptors, NTRK, GRIK, and NMDAR, act at synapses to regulate synaptic function. NCAM2 and CNTNAP2, also have functions in regulating neurite outgrowth. (3) Signaling molecules (blue ellipse shape): CDKL5, DYRK1A, and PTEN regulate several signaling pathways to maintain the stability of dendritic structures. (4) Scaffolding proteins (yellow polygon): SHANK3 and DLGAP2, locate at post-synaptic density and tightly associate with PSD95 and other signaling molecules to regulate spine stability and synaptic plasticity. (5) Synaptic proteins (pink ellipse shape): STXBP5 and PRICKLE1 not only regulate synaptic vesicle release, but also play a role in regulating neurite outgrowth. (6) Syndromic molecules (clear rectangular box): FMRP and UBE3A regulate the structural stability of neurons via the regulation of protein synthesis or binding with other molecules in dendritic spines. MECP2 mainly functions in the nucleus and regulates transcription of many genes to in turn affecting the structural stability of neurons. TSC1/2 regulates the mTOR pathway and cytoskeletal machinery to maintain dendritic stability.](fncel-10-00263-g002){#F2}

Cytoskeletal Regulation Is Key to the Maintenance of Proper Stability and Plasticity of Neurons
===============================================================================================

The actin and microtubule cytoskeletons are the major components of dendritic spine and neurite structure, respectively ([@B259]; [@B260]; [@B161]; [@B546]). Precise regulation of these actin and microtubule networks is thus central to guide the proper development, plasticity, and long-term stability of these structures ([@B383]; [@B384]; [@B368]; [@B356]; [@B322]; [@B357]; [@B563]; [@B161]; [@B428]; [@B462]; [@B464]; [@B521]).

Actin and Microtubule Regulators Are Associated with Autism
-----------------------------------------------------------

Myosins are motors that utilize ATPase activity to provide motility of actin or cargo transport on actin filaments ([@B476]; [@B439]; [@B595]). Several myosin isoforms play central roles in regulating neurite outgrowth, as well as dendritic spine structural plasticity ([@B656]; [@B655]; [@B510]; [@B237]; [@B317]; [@B672]; [@B324]; [@B597]). Among all isoforms, *MYO16* (Myr8 or NYAP3) was recently implicated in ASD ([@B637]; [@B132]; [@B305]; [@B498]; [@B362]). MYO16 is expressed predominantly in the cortex and cerebellum. Levels and phosphorylation of MYO16 protein peak during early developmental stages, consistent with a role in regulating neuronal migration and neurite extension ([@B456]; [@B670]). In addition to binding directly to filamentous- (F-)actin, MYO16 also physically interacts with PI3K and WAVE complex to regulate stress fiber remodeling in fibroblasts as well as the adhesion-dependent neurite outgrowth in neurons ([@B670]).

*CTTNBP2* encodes cortactin-binding protein 2 that interacts with cortactin, a nucleation-promoting factor of actin ([@B437]). CTTNBP2 is highly expressed in dendritic spines where it locally interacts with cortactin, striatin, a calcium binding protein, and PP2A, a serine/threonine protein phosphatase 2A, to control the formation and the maintenance of dendritic spines ([@B107]; [@B108]; [@B262]). In addition, oligomerization of CTTNBP2 induces microtubule bundling to promote dendrite arborization ([@B542]). Several mutations of *CTTNBP2* have been reported in ASD cases, further indicating the importance of neurite outgrowth and dendritic spine formation for proper brain function ([@B111]; [@B280]; [@B153]).

Activity-dependent neuroprotective protein (ADNP) is a homeobox-containing protein secreted from glia and neurons ([@B38]; [@B678]; [@B203]; [@B374]; [@B411]). Through its interaction with the chromatin remodeling complex SWI/SNF, ADNP regulates hundreds of genes to modulate brain function ([@B472]; [@B372]; [@B373]). In addition to its traditional role in regulating transcription, ADNP has also been suggested to have function in regulating dendritic spines through interactions with microtubule end binding proteins ([@B446]). Mutations in or the alteration of the protein expression of *ADNP* have been associated with several neurological disorders, including schizophrenia and Alzheimer's Disease ([@B627]; [@B189]; [@B170]; [@B663]). Intriguingly, the association of mutations in *ADNP* and ASD is further emphasizing that the cytoskeletal integrity of neurons is vulnerable in ASD ([@B442],[@B443]; [@B48]; [@B153]; [@B251]; [@B611]; [@B164]).

Small RhoGTPase Regulation Is a Key Mechanism in Controlling Neurite and Spine Stability
----------------------------------------------------------------------------------------

Small RhoGTPases including Rho, Rac, and Cdc42 are central cytoskeletal regulators that control cell motility and morphology ([@B223]; [@B425]; [@B357]; [@B586]). Genetic mutations or dysregulation of the small RhoGTPase regulators, including guanine-exchange factors (GEFs) and GTPase-activating proteins (GAPs), have been implicated in several neurological conditions, including ASD ([@B425]; [@B357]; [@B18]; [@B556]). Here, we will highlight those that regulate the morphological stability of neurons.

Engulfment and cell motility 1 (ELMO1) was first identified in a complex with a RacGEF, DOCK180, to activate Rac1 activity, which is essential for cell migration and phagocytosis ([@B231]; [@B75]; [@B226]). In hippocampal neurons, ELMO1 and DOCK180 colocalize at synaptic sites and together are required for spine formation ([@B311]). Loss of *Elmo1* shows a reduction in spine number but increased filopodia, suggesting a role in formation and/or maintenance of mature spines ([@B311]). In addition, ELMO1 has been shown to regulate axonal and dendritic branching via Rac1 activation in response to different upstream signals ([@B194]; [@B332]).

*SYNGAP1* encodes a synaptic-specific Ras/Rap GAP that associates with PSD-95 and specifically localizes to synaptic sites ([@B310]; [@B325]). The role of SYNGAP1 in regulating spine morphology and synaptic function has been well described. In response to CaMKII phosphorylation, SYNGAP1 directly regulates Ras/Rap activity to modulate MAPK signaling to maintain the stability of dendritic spines ([@B103]; [@B325]; [@B435]; [@B506]). Overexpression of SYNGAP1 decreases AMPAR-mediated currents and surface expression ([@B506]; [@B633]). Deletion or reduction of SYNGAP1 results in an elevated synaptic strength and an increase of mushroom spines ([@B618]; [@B506]; [@B89]). Mice with *Syngap1* haploinsufficiency show accelerated maturation of dendritic spines followed by disruptions of synaptic transmission and cognitive function ([@B120], [@B121]; [@B448]; [@B1]). Coincidentally, haploinsufficiency in *SYNGAP1* has been found in individuals with autism, intellectual disability, and a specific form of epilepsy ([@B55]). Several other *de novo* mutations of *SYNGAP1* also have been identified in different cases of ASD ([@B474]; [@B135]; [@B236]; [@B55]; [@B647]; [@B72]; [@B153]; [@B441]).

Since the actin and microtubule cytoskeletons are the major components of neuronal processes, it is not surprising that manipulating the cytoskeletal machinery dramatically affects neuronal structures. A small imbalance of cytoskeletal dynamics will create a huge impact on the structural stability of neurons, which in turn alters the formation of neuronal circuitry. Interestingly, most autism-associated cytoskeletal regulators control neurite outgrowth and synapse/spine formation thereby affecting the structural stability of neurons. These two processes are also the initial steps to establish correct neuronal connections during development. Failure to regulate these processes properly may result in significantly altered wiring of brain circuitries that is often found in ASD. The next research focus should investigate early in development to connect the dysregulatory effects of mutations in cytoskeletal genes.

*Trans*-Synaptic Adhesion Molecules Play Important Roles in the Regulation of Neuronal Stability
================================================================================================

Cell adhesion molecules (CAMs) play crucial roles in many aspects of neural circuit formation and, thus, it comes as no surprise that these molecules are found as top hits in lists of autism risk genes ([@B56]; [@B474]; [@B270]; [@B104]). Here, we discuss the current understanding of how CAMs that belong to the cadherin-, the neurexin/neuroligin- and the immunoglobulin-superfamily regulate neuronal stability.

Cadherin Superfamily Members Are Prominent Hits in Autism Risk Gene Lists
-------------------------------------------------------------------------

The genetic association of cadherins with autism strongly supports their central roles in the development of the nervous system including synaptogenesis, dendrite arborization and dendritic spine regulation ([@B20]; [@B562]; [@B39]; [@B196]; [@B531]). The cadherin superfamily is comprised of more than a hundred different genes, subdivided into several classes including classical cadherins, protocadherins and atypical cadherins ([@B266]; [@B252]). Several copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) are found in classical cadherins: *CDH2. CDH5. CDH8. CDH9, CDH10, CDH11*, and *CDH13* ([@B638]; [@B98]; [@B270]; [@B450]; [@B518]; [@B443]; [@B481]; [@B132]; [@B629]; [@B139]; [@B327]); non-clustered protocadherins: *PCDH9, PCDH10*, and *PCDH19* ([@B404]; [@B162]; [@B86]; [@B443]; [@B483]; [@B216]; [@B607])*;* and an atypical cadherin, *FAT1* ([@B270]; [@B420]; [@B142]; [@B305]). In general, the extracellular domain of cadherins contains five cadherin repeats/EC motifs that mediate Ca^2+^-dependent homophilic adhesion ([@B576]). However, heterophilic interactions between different sub-classes of classical cadherins create more combinations of interaction and function ([@B544]). The cytosolic tail binds to catenins leading to the anchoring of the cadherin-catenin complex to the cytoskeleton (via β-catenin and α-catenin) and the clustering of cadherins in the plasma membrane (via p120-catenin) ([@B664]; [@B422]; [@B386]). The cadherin superfamily contains numerous cadherin members which impact neuronal structure and function from early neurite extension to the maintenance of mature synaptic networks ([@B39]; [@B196]). However, the pathways underlying disrupted cadherin signaling still requires further investigation. Here, we focus our discussion on the autism-associated cadherins shown to regulate neurite outgrowth and synapse morphogenesis.

*N*-cadherin, also known as cadherin 2 (CDH2), is the best studied classical cadherin. *N*-cadherin functions throughout the development of the nervous system, including neurite outgrowth, axon guidance, synaptogenesis and synaptic plasticity ([@B570]; [@B20]; [@B252]; [@B196]). *N*-cadherin promotes dendritic outgrowth during development and is also required for activity-dependent dendrite expansion ([@B179]; [@B574]). *N*-cadherin is also required for the establishment of initial contacts between axons and filopodia followed by clustering at contact points to stabilize early synapses ([@B50]; [@B268]; [@B585]). Blocking *N*-cadherin adhesion in hippocampal neurons perturbs synapse formation and abolishes long-term potentiation (LTP)-induced stabilization of dendritic spines ([@B585]; [@B392]). Neural activity increases *N*-cadherin protein levels and dimerization leading to increased synapse number ([@B69]). In mature synapses, *N*-cadherin is required for the persistence of dendritic spine enlargement and LTP ([@B69], [@B70]). Together with *N*-cadherin, CDH8 regulates the development of the hippocampal mossy fiber pathway ([@B44]). CDH8 also mediates assembly and maturation of corticostriatal synapses ([@B44]; [@B197]), whereas CDH9-mediated adhesion is involved in the formation and differentiation of dentate gyrus synapses on CA3 cells where it regulates synapse density, presynaptic bouton complexity and postsynaptic morphology ([@B646]). In contrast to CDH8 and CDH9, an RNAi screen for molecules required for synapse development identified CDH11 and CDH13 as positive regulators of glutamatergic synapse development ([@B454]). Interestingly, *Cdh11*-deficient mice revealed enhanced LTP in the CA1 region of the hippocampus and mice show reduced fear- or anxiety-related behavior suggesting that CDH11 might restrict synaptic plasticity and efficacy ([@B371]).

Protocadherins are the largest subgroup within the cadherin superfamily and are further subtyped into clustered (α-, β- and γ-PCDH) and non-clustered protocadherins (δ1- and δ2-PCDH) ([@B193]). They share a similar structure to classical cadherins, but with six to seven cadherin domains/EC motifs. However, the cytosolic tails of protocadherins and cadherins do not show significant homology suggesting that they likely engage distinct intracellular signaling pathways. Protocadherins are highly expressed in the nervous system and localize to synapses. Based on their spatial and temporal expression pattern in the brain and on recent reports, protocadherins have roles in dendritic development and synaptic connections ([@B253]; [@B193]; [@B312], [@B313]; [@B302]). For example, PCDH10 expression is regulated by neuronal activity and its function is crucial for forebrain axon outgrowth and the proper patterning of thalamocorticial projections ([@B596]; [@B404]). In addition, PCDH10 mediates synapse elimination by promoting proteasomal degradation of PSD-95 ([@B591]).

FAT atypical cadherin 1 (FAT1) belongs to the atypical cadherin family and consists of a huge extracellular domain comprising 34 cadherin domains/EC motifs ([@B578]; [@B511]). FAT1 expression is enriched during embryonic neurodevelopment and severe nervous system defects are found in FAT1-deficient mice ([@B119]; [@B511]). At the cellular level, FAT1 localizes to cell--cell contacts as well as to the leading edge of lamellipodia and tips of filopodia to regulate cell polarity, cell migration, and cell-cell adhesion ([@B399]; [@B577]). These functions are likely mediated through intracellular signaling via Ena/VASP proteins to regulate actin assembly and dynamics ([@B399]; [@B577]). Other intracellular binding partners of FAT1 include the classical cadherin binding partner β-catenin as well as the synaptic scaffolding molecules Homer-1 and 3 ([@B261]; [@B528]).

The Neurexin-Neuroligin Complex Is One of the Most Studied *Trans*-synaptic Adhesion Pairs in Autism
----------------------------------------------------------------------------------------------------

Neurexins are encoded by three genes (*NRXN1-3*) while the neuroligin family consists of four isoforms in mice (*Nlgn1-4*) and five isoforms in humans (*NLGN1-4X and 4Y*) ([@B560]). Neurexins localize to presynaptic terminals and form heterophilic interactions with neuroligins, which are localized to the postsynaptic compartment ([@B275], [@B276]; [@B427]). Presynaptic neurexins link synaptic adhesion with the synaptic vesicle release machinery via binding to PDZ-domain containing proteins ([@B241]; [@B82]; [@B156]; [@B398]). At the postsynaptic site, the neurexin-neuroligin complex induces clustering of scaffolding proteins, such as PSD-95, and recruits NMDA- and AMPA-receptors ([@B281]; [@B113]; [@B413]; [@B249]; [@B36]; [@B402]). Distinct neurexin-neuroligin complexes play discrete roles during synaptogenesis with neuroligin-1 regulating excitatory synapse formation and maturation, while neuroligin-2 and 3 mediate inhibitory synapse formation ([@B551]; [@B527]; [@B482]; [@B616], [@B615]; [@B113]; [@B346]; [@B36]; [@B330]; [@B222]). Intriguingly, neurexin-1 can also bind to leucine-rich repeat transmembrane protein 2 (LRRTM2) and promote synapse formation ([@B155]; [@B318]; [@B222]). In addition to their synaptic roles, interaction of neurexin-1 and neuroligin-1 regulates neurite outgrowth ([@B218]). Several mutations and CNVs in *NRXN1-3* have been found to be associated with ASD with the prevalence highest for mutations in *NRXN1* ([@B187]; [@B25]; [@B309]; [@B660]; [@B114]; [@B474]; [@B650]; [@B210]; [@B626]; [@B87]; [@B172]; [@B280]; [@B321]; [@B361]; [@B483]; [@B525]; [@B599]; [@B46]; [@B146]; [@B216]; [@B290]; [@B323]; [@B629]; [@B142]; [@B153]; [@B176]; [@B278]; [@B623]; [@B573]). Similarly, *NLGN1-4* genes have been implicated in the pathogenesis of ASD with *NLGN3* and *4* being the most prevalent ([@B285]; [@B335]; [@B669]; [@B337]; [@B219]; [@B675], [@B676]; [@B338]; [@B443]; [@B558]; [@B661]; [@B216]; [@B290]; [@B279]; [@B305]; [@B349]; [@B327]; [@B519]; [@B677]). However, several reports also indicate the negative association of *NLGN3* and *4* with autism ([@B624]; [@B209]; [@B59]; [@B643]; [@B26]; [@B359]; [@B657]). Further investigation is required to clarify this controversy.

Mutations in another member of the neurexin superfamily, contactin-associated protein-like 2 (*CNTNAP2/CASPR2*), have also been identified in individuals with autism ([@B4]; [@B21]; [@B31]; [@B621]; [@B353]; [@B469]; [@B478]; [@B431]; [@B440]; [@B461]; [@B644]; [@B15]; [@B483]; [@B216]; [@B516]; [@B176]; [@B477]; [@B115]). CNTNAP2 is required for dendrite arborization and dendritic spine development and maintenance ([@B14]; [@B212]). Mice deficient for *Cntnap2* show defects in spine stabilization and synaptic function resulting in several core ASD-like behaviors such as deficits in communication and social interaction, as well as repetitive behaviors ([@B461]; [@B212]; [@B613]).

Immunoglobulin Superfamily of Cell Adhesion Molecules Participate Largely in Neuronal Circuit Formation
-------------------------------------------------------------------------------------------------------

The immunoglobulin superfamily of CAMs (IgSF-CAMs), including contactin, L1CAM, NCAM or SynCAM, make up a third large group of *trans*-synaptic CAMs. IgSF-CAMs have been implicated in various processes during neural circuit formation, from neurite outgrowth and axonal navigation to synapse formation and plasticity ([@B503]).

The contactin (CNTN) subfamily consists of six members (CNTN1-6), each of which contain six Ig-like and four fibronectin III-like domains that are linked to the cell membrane via a glycosylphosphatidylinositol (GPI)-anchoring domain ([@B543]). While CNTN1 and 2 have been extensively studied in the context of neurite outgrowth, fasciculation, and axon guidance, less is known about the function of CNTN3-6 ([@B299]; [@B543]; [@B401]). However, *CNTN3-6* have been implicated as risk genes in ASD ([@B188]; [@B117]; [@B404]; [@B219]; [@B502]; [@B138]; [@B270]; [@B604]; [@B338]; [@B483]; [@B599]; [@B142]; [@B300]; [@B418]; [@B477]; [@B263]; [@B360]). CNTN4 is strongly expressed in a subset of olfactory sensory neurons where it guides proper targeting of axon terminals to the corresponding glomeruli for the formation of olfactory circuits ([@B297]). The *Cntn5* knockout mice display reduced fiber density and glutamatergic synapses in the auditory brainstem ([@B347]; [@B588]). CNTN6 is highly expressed in the postnatal cerebellum and plays an important role in the formation of synapses between parallel fibers and Purkinje cells ([@B569]; [@B514]). Similarly, CNTN6 regulates the formation of glutamatergic synapses in the hippocampus and the orientation of apical dendrites of layer V pyramidal neurons in the visual cortex ([@B666]; [@B513]).

Neural cell adhesion molecule 2 (NCAM2) belongs to the NCAM family and is a paralog of NCAM1. Similar to other members of the Ig-superfamily, NCAMs contain five Ig- and two FN3-domains in the extracellular region and are differentially spliced to produce both transmembrane and GPI-anchored variants ([@B649]). NCAM2 is predominantly expressed in the brain and required for the formation and maintenance of axonal and dendritic compartmentalization in the olfactory glomeruli ([@B632]; [@B67]). In addition, NCAM2 regulates filopodia formation and neurite branching of cortical neurons via a CaMKII-dependent signaling pathway ([@B536]). SNP and chromosomal deletion including *NCAM2* has been reported in individuals with autism ([@B235]; [@B270]; [@B467]).

Adhesion molecules are a huge group of proteins that display many similarities in molecular structure and in signaling property. Depending on the cellular localization, functions of adhesion molecules range from neurite outgrowth and synapse/spine formation, to neuronal plasticity, further highlighting their importance in regulating the structural stability of neurons. However, whether these molecules function to compensate each other or are developmentally regulated is still not clear. The interesting question is whether the temporal and spatial expression patterns of these autism-associated adhesion molecules correlate with the affected developmental time frame and affected brain regions in ASD.

Surface Receptors Signal Through Intracellular Signaling Pathways to Regulate Neuronal Stability
================================================================================================

Establishment of synaptic connections and modification of their strength and stability is intimately related to the receptor populations in the plasma membranes of pre- and postsynaptic cell compartments. Thus, several ASD risk genes code for cell surface receptor proteins including the ionotropic glutamate receptors (iGluR) and the receptor tyrosine kinases (RTK).

Glutamate Receptors: GRIN2B and the GRIK Genes
----------------------------------------------

Glutamate-mediated ionotropic signaling occurs via activation of the glutamate-gated ion channel family which is divided into three subfamilies; the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), the *N*-methyl-[D]{.smallcaps}-aspartate receptors (NMDARs) and the kainate-type receptors (KARs) ([@B129]). The main function of these receptors focuses on the regulation of synaptic activity and plasticity, which in turn affect the structural stability of neurons. In particular, the genetic association of the *GRIN2B* gene, which encodes the GluN2B subunit of NMDARs, and the *GRIK2/4* genes that encodes the GluK2 and 4 subunits of KARs with autism has been established ([@B284]; [@B547]; [@B257]; [@B407]; [@B440], [@B442]; [@B579]; [@B152]; [@B227]; [@B483]; [@B572]; [@B671]; [@B165]; [@B153]; [@B305]; [@B349]; [@B414]; [@B477]; [@B6]; [@B453]).

NMDARs are composed of an obligatory GluN1 subunit and one or more GluN2 (GluN2A-GluN2D) subunits with the majority of the composition being GluN1/2A/2B ([@B77]; [@B468]; [@B367]). The composition of GluN2 subunits are developmentally regulated and critically determine the synaptic properties ([@B336]; [@B537]; [@B351]). The GluN2B subunit expresses early during development gradually being replaced by GluN2A indicating its role in the formation of neuronal circuitry ([@B537]; [@B351]; [@B80]). Overexpression or knockdown of GluN2B alters dendrite arborization in neurons both *in vivo* and *in vitro* ([@B184]; [@B180]; [@B532]; [@B80]). GluN2B is also required for the formation of dendritic spines, maturation of synapses, and the proper molecular compositions of several postsynaptic proteins ([@B2]; [@B180]; [@B73]; [@B304]). In turn, GluN2B is crucial for maintaining proper synaptic plasticity ([@B73]; [@B436]; [@B634]; [@B662]; [@B509]; [@B173]). *GRIN2B*, an autism-risk gene, further suggests that pathways involved in early circuitry formation may be vulnerable targets in autism. Selective inhibition of GluN2B function has been shown to restore dendritic spine loss and associated behavior alterations in several experimental conditions providing insights to the potential therapeutic targets to correct some ASD phenotypes ([@B101]; [@B273]; [@B232]).

Kainate-type receptors regulate axonal filopodia motility of hippocampal mossy fibers in response to neuronal stimulation during synaptogenesis ([@B580]). KAR subunits, in particular GluK2, interacts with structural elements of the synapse; such as the PSD-95 and SAP-102 scaffolding molecules, as well as the *N*-cadherin and β-catenin adhesion molecules ([@B92]; [@B451]), indicating that *Grik* genes are involved in processes that regulate synapse architecture and stability. Indeed, GluK2 regulates hippocampal synapse maturation and stability ([@B264]; [@B133]; [@B331]; [@B342]). Animals with deficient GluK2 proteins exhibit a delay in the postnatal maturation of synaptic contacts between MF-CA3 in the hippocampus, suggesting that the expression of the GluK2 is important for the establishment of normal morphology and function of synaptic networks in the hippocampus ([@B134]; [@B331]). Expression of the GluK4 is mainly restricted to mossy fiber synapses in the hippocampal CA3 region where it co-assembles with GluK2 in functional pre- and postsynaptic GluK2/4 receptor complexes ([@B149]). Mice with forebrain GluK4 overexpression exhibit altered synaptic transmission and display several autistic-like behaviors including social impairment, enhanced anxiety, and depressive states, coinciding with the finding of *GRIK4* duplications in individuals with ASD ([@B227]; [@B6]). Even though the phenotypes resulting from *Grik* gene dysfunction in mice are in the same general categories with symptoms of ASD, further investigation about the molecular consequences of impairments in GluK proteins in ASD is required for developing future therapeutic interventions.

Receptor Tyrosine Kinases: The NTRK Genes
-----------------------------------------

Tyrosine receptor kinases (Trks) mediate neurotrophic growth factor-induced signaling via dimerization and trans-autophosphorylation of Tyr residues on the intracellular domains of the receptor and subsequent activation of intracellular signaling pathways ([@B157]). This results in a number of neurogenic events, such as synaptic plasticity, maturation and stability, dendritic and axonal growth and differentiation as well as cell survival and maintenance ([@B381]; [@B157]). The Trk family consists of three proteins; TrkA, B and C, which are expressed by the neurotrophic tyrosine receptor kinase genes (*NTRK. 1. 2* and *3*, respectively. Each Trk receptor interacts selectively with a different neurotrophin resulting in preferential interaction pairs: TrkA is activated by NGF, TrkB by BDNF, and TrkC by NT-3 ([@B157]). Considering its well-documented function in synaptophysiology ([@B397]), it would be reasonable to suspect a correlation between genetic variations in *NTRK2* and ASD. However, to date, only one study has reported a weak association between *NTRK2* mutations and ASD ([@B137]), while other studies were unable to confirm that link ([@B95]). Alternatively, a growing body of evidence generated from genetic evaluation of ASD risk genes has identified *NTRK3*, the gene coding for TrkC, as a plausible candidate in autism ([@B95]; [@B270]; [@B612]).

In the mammalian brain, TrkC (as well as other neurotrophic receptors) is present both as full length catalytically active receptor, as well as a splice variant that lacks the Tyr kinase domain and is catalytically inactive ([@B274]). Interestingly, knockout of the non-catalytic TrkC isoform in mice yields a more severe phenotype than does the depletion of the kinase-active receptor, indicating that TrkC has important functions beyond the ability to convey classical RTK signaling ([@B185]; [@B157]). Indeed, recent studies have begun to elucidate the function assigned to non-catalytic isoforms by demonstrating a role for TrkC in synaptic adhesion complexes ([@B568]). Postsynaptic TrkC interacts across the presynaptic cleft with protein tyrosine phosphatase (PTP) σ to form an adhesion complex crucial for development and stability of excitatory, but not inhibitory, synapses ([@B567]; [@B128]). Formation of this adhesion complex is enhanced by the presence of the TrkC ligand, NT-3, which facilitates glutamatergic presynaptic assembly and function ([@B12]). NT-3 binding to kinase domain-truncated TrkC isoforms has also been shown to induce cytoskeletal changes via recruitment of the scaffold protein tamalin, leading to activation of Arf6 and induction of Rac1-GTP ([@B181]). Interestingly, the expression of non-catalytic TrkC relative to the kinase active isoform is upregulated during the second and third postnatal weeks, the most intense period of synaptogenesis, indicating that expression of the different *Ntrk3* gene products is temporally associated with synapse formation ([@B600]; [@B393]). Recent studies also found that NT-3-TrkC signaling between presynaptic granule neurons and postsynaptic Purkinje cells controls dendrite morphogenesis in cerebellum ([@B295]). Although no studies have evaluated the ratio of non-catalytic to catalytic TrkC receptors in individuals with ASD, it might be speculated that certain genetic variants could cause imbalances in the expression patterns of *NTRK3* isoforms.

Surface receptors respond to extracellular signals such as neurotransmitters and trophic factors to activate downstream signaling pathways to diversify the cellular responses. Each receptor may have a unique signaling pathway associated with it and therefore, the mutations on selective receptors provide us with clues about which signaling pathways may be more susceptible to perturbations in ASD. Thus, identifying the downstream effectors and signaling pathways that are affected by these autism-associated receptor mutants should be an important direction of future investigation.

Signaling Molecules Actively Regulate Dendritic Spine and Dendrite Morphology
=============================================================================

Protein Kinases
---------------

The dual-specificity tyrosine-(*Y*)-phosphorylation-regulated kinase 1a (DYRK1A) is one of the isoforms in DYRK family and is a human homolog of the *Drosophila* kinase minibrain (MNB) ([@B545]). *DYRK1A* was first described as a cadidate gene for intellectual disability in Down syndrome because of its location on the "Down syndrome critical region" of chromosome 21 ([@B603]; [@B545]; [@B238]). Interestingly, recent genetic analyses suggest that *DYRK1A* is also a risk gene in ASD ([@B280]; [@B442],[@B443]; [@B102]; [@B326]; [@B494]; [@B74]; [@B602]). Expression of *Dyrk1a* in mouse brain is limited to early developmental periods and can promote neurite formation ([@B438]; [@B238]; [@B220]). In addition, DYRK1A phosphorylates N-WASP, a cytoskeletal protein, to inhibit spine formation in primary hippocampal neurons ([@B455]). Pyramidal neurons in *Dyrk1a^+/-^* mouse cortex have reduced dendritic branches and dendritic spine density, which potentially causes the reduced brain size in these mice ([@B192]; [@B47]). On the other hand, overexpression of DYRK1A in mice causes increased spine density in cortical pyramidal neurons, and these animals show prefrontal deficits including significant impairment of spatial learning and cognitive flexbitiliy ([@B7]; [@B582]). However, overexpressing DYRK1A in primary cortical mouse neurons significantly reduces dendrite complexity through disruption of REST/NRSF levels and REST/NRSF-SWI/SNF chromatin remodeling complex ([@B341]).

The Cyclin-dependent kinase-like 5 (CDKL5) is a serine/threonine kinase, also known as serine/threonine kinase 9 (STK9). Mutations of *CDKL5* have been associated with several X-linked neurodevelopmental disorders, as well as ASD ([@B641]; [@B524]; [@B19]; [@B508]; [@B553]; [@B526]; [@B28]; [@B37]; [@B375]; [@B93]; [@B178]; [@B475]; [@B682]; [@B124]; [@B565]). Expression of CDKL5 is enriched in the brain and increases gradually following development ([@B355]; [@B507]). In addition to a catalytic domain, CDKL5 contains nuclear localization and export signals and can shuttle between the cytoplasm and nucleus. In the nucleus, CDKL5 phosphorylates methyl-CpG-binding protein 2 (MECP2), a causative gene for Rett syndrome (see below), providing a suggestive molecular mechanism associated with the condition ([@B378]). In the cytosol, CDKL5 postively regulates neurite outgrowth and dendritic arborization via binding with Rac1 ([@B106]). With this broad influence on neuronal function, *Cdkl5* null mice have several defects ranging from neuronal survival, dendritie maturation, spine stability, synaptic plasticity, and behaviors ([@B8]; [@B200]; [@B159]). Treatment of *Cdkl5* null mice with insulin-like growth factor 1 (IGF-1) or the glycogen synthase kinase 3β (GSK3β) inhibitor can rescue these defective phenotypes ([@B159]; [@B199]). Furthermore, CDKL5 has been shown to bind to palmitoylated-PSD-95 and this interaction is important for synaptic targeting of CDKL5 and spine formation ([@B687]).

Phosphatase: PTEN
-----------------

Phosphatase and tensin homolog (PTEN) is a dual-specificity lipid/protein tyrosine phosphatase that negatively regulates the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway to control cellular function ([@B369], [@B370]; [@B554]; [@B617]; [@B169]; [@B343]; [@B255]). PTEN was first identified as a tumor suppressor ([@B350]) but later also found to be associated with neurodevelopmental conditions such as epilepsy, macrocephaly, and autism ([@B221]; [@B81]; [@B84]; [@B444]; [@B614]; [@B385]; [@B493]; [@B557]; [@B526]; [@B443]; [@B79]; [@B153]; [@B254]; [@B376]; [@B610]; [@B124]; [@B164]; [@B293]; [@B327]; [@B552]; [@B573]; [@B144]; [@B529]; [@B583]). PTEN expression in the brain is positively correlated with the developmental stages of neuronal dendrite formation and synaptogenesis suggesting a role in regulating neuronal function ([@B465]). PTEN plays a critical role in regulating the stability of dendritic spines and synaptic activity. PTEN overexpression in hippocampal CA1 pyramidal neurons results in a decrease in spine density ([@B681]). Deleting PTEN in cortical and hippocampal neurons causes loss of neuronal polarity and general neuronal hypertrophy, including increases in dendrite arborization and spine density ([@B286]; [@B329]; [@B195]; [@B685]). Selective deletion of PTEN in dentate granule neurons results in increased spine density and synaptic activity, as well as increased mossy fiber sprouting ([@B366]; [@B485]). Knockdown of PTEN in basaolateral amygdala and dentate gyrus, however, does not affect spine density, but spine morphology is dramatically altered with an increase of mature mushroom-shaped spines ([@B243]). The *Pten* knockout in cerebellum also results in significant alterations in neuronal morphology of Purkinje cells including swelling of dendrites, and an increase of axonal bouton and dendritic spine size ([@B144]). The impact of PTEN on spine stability is dependent on the phosphorylation status of its serine/threonin residues and the PDZ-binding motif in its C-terminus ([@B681]). The phenotypes observed following PTEN deletion result from hyperactivation of the PI3K/AKT/mTOR pathway and inhibition of this molecular pathway is sufficient to rescue these phenotypes ([@B286]; [@B329]; [@B685]; [@B485]).

The identification of the vulnerable intracellular signaling pathways will aid us in the pursuit to find new therapeutic drug targets in patients with ASD. Interestingly, a variety of gene mutations result in disruption of the mechanistic pathways that these signaling molecules participate in. Therefore, several of the experimental pharmacological agents currently proposed as possible treatment strategies for autistic phenotypes are targeting these signaling molecules (see "Perspectives").

Synaptic Proteins Regulate Synaptic Function to Maintain Neuronal Stability
===========================================================================

Scaffolding Proteins Provide Supporting Roles to Connect Structural and Signaling Molecules
-------------------------------------------------------------------------------------------

Synaptic signaling processes are key to proper neural function. Some pivotal components of synapses are postsynaptic scaffolding proteins, which cluster neurotransmitter receptors, cell adhesion proteins, ion channels and cytoskeletal molecules to a confined postsynaptic region ([@B307]; [@B538]). Dysfunction in scaffolding proteins often has a huge impact on neuronal function, including neuronal morphology and synaptic plasticity ([@B584]). Emerging evidence has recently linked ASD with mutations of several genes encoding scaffolding proteins as described below.

*SHANK* genes encode three large scaffolding proteins, SHANK1-3, that contain ankyrin repeats, the SH3 domain, the PDZ domain, the proline-rich domain, and the SAM domain ([@B410]; [@B539]; [@B35]). These multiple putative protein interaction domains enable shank proteins to function as a bridge linking inotropic glutamate receptors, PSD-95, SAPAPS ([@B410]), Homers ([@B593]; [@B244]) and the cytoskeleton ([@B62]; [@B488]). Altered function of all three *SHANK* genes have been implicated in autism, with *SHANK3* showing the highest prevalence ([@B400]; [@B211]; [@B27]; [@B51], [@B52]; [@B474]; [@B526]; [@B628]; [@B338], [@B339]; [@B483]; [@B520]; [@B522]; [@B61]; [@B323]; [@B125]; [@B153]; [@B230]; [@B349]; [@B123]; [@B327]; [@B423]; [@B677]). In general, SHANK2 and 3 promote dendritic spine formation, whereas SHANK1 promotes dendritic spine head size enlargement ([@B515]; [@B504]; [@B267]; [@B622]). SHANK3 also binds to a synaptic scaffold, Densin-180, to inhibit the Densin-180-induced dendrite arborization ([@B489]). Disruption of the *SHANK3* gene is associated with the 22q13.3 deletion syndrome, characterized by severe expressive-language delay and mild cognitive challenges ([@B65]). Several genetically manipulated *Shank3* mutant mouse models were developed to study the role of *SHANK3* mutations in ASD ([@B33]; [@B458]; [@B635]; [@B289]; [@B459]). Neurons in these mice have morphological alterations in dendritic spines resulting in LTP deficiency and defects at striatal synapses. Furthermore, these animals display several behavioral deficits including abnormal vocalization, dyadic social interaction, and compulsive-repetitive behaviors. Intriguingly, re-expressing *Shank3* in adulthood is sufficient to restore parts of the autism-related phenotypes in mice ([@B390]). This study sheds light on the application of gene therapy for individuals with *SHANK3* mutations. Mechanistically, several actin regulators including Abp1, cortactin, cofilin, and Rac1, have altered expression or activity associated with *Shank3* deficiency or autism-related mutations that contribute to dendritic spine reduction and synaptic dystrophy ([@B234]; [@B174]; [@B171]).

Disks large-associated protein 2 (DLGAP2), also known as synapse-associated protein 90/postsynaptic density-95-associated proteins (SAPAP2), is a postsynaptic adapter protein in mammalian brains ([@B314]). DLGAP2 directly interacts with DLG4 (also known as PSD-95) and Shank proteins to form the Dlg4-Dlgap-Shanks complex important for maintaining the PSD structure ([@B306]; [@B571]; [@B63]). The *Dlgap2^-/-^* mice have reduced spine density in the orbitofrontal cortex accompanied with downregulation of synaptic proteins, Homer1 and αCaMKII, as well as receptors, NR1 and GluR1, and exhibit exacerbated aggressive behaviors ([@B291]). Molecular and genetic studies have demonstrated that alterations in *DLGAP2* are involved the pathophysiology of various psychiatric conditions, including schizophrenia, Alzheimer's disease, post-tramautic syndrome, and pediatric obsessive-compulsive disorder ([@B110]; [@B654]; [@B352]; [@B100]). Rare *de novo* CNVs, deletions, and duplications of *DLGAP2* have been reported in individuals with ASD, but how mutations of *DLGAP2* contribute to autism is still largely unknown ([@B380]; [@B447]; [@B112]; [@B474]; [@B142]).

Molecules Regulating Synaptic Vesicles Are Implicated in the Regulation of Neurite Outgrowth
--------------------------------------------------------------------------------------------

Neurotransmitter release is regulated by the cycling of synaptic vesicles at the axonal terminal. The regulation of synaptic vesicles contains several steps and requires precise interaction of several specialized proteins, including SNARE complex for membrane fusion and syntaxin for vesicle docking. *STXBP5* encodes a syntaxin-binding protein, tomosyn that negatively regulates neurotransmitter release by forming a syntaxin-SNAP25-tomosyn complex ([@B201]; [@B512]; [@B668]; [@B658], [@B659]; [@B57]). Neuron-specific tomosyn deletion in mouse hippocampal dentate gyrus impairs spatial learning and memory, whereas tomosyn knockdown in dentate gyrus decreases synaptic plasticity of mossy fibers ([@B34]; [@B49]). Tomosyn also regulates SNARE complexes via ROCK phosphorylation of syntaxin-1 to control neurite outgrowth ([@B512]). Recent genetic studies have identified the association of *STXBP5* and ASD ([@B150]; [@B142]; [@B153]).

*PRICKLE1* encodes PRICKLE1 protein, which has been traditionally thought to regulate the Wnt/beta-catenin signaling pathway to control epithelial planar cell polarity and cell migration during neural tube formation ([@B250]; [@B91]; [@B619]; [@B287]). Intriguingly, the *Prickle1^+/-^* mice exhibit autism-like behaviors, which may result from disrupted interaction with synapsin, a regulator of neurotransmitter release, suggesting that PRICKLE1 plays a critical role in synaptic vesicle regulation ([@B449]). In addition, knockdown of PRICKLE1 in mice results in reduced axonal and dendrite formation in hippocampal neurons ([@B358]). More recently, variants of *PRICKLE1* have been found in individuals with autism ([@B142]; [@B587]).

Synaptic scaffolds are crucial not only to maintain the structural stability of dendritic spines and synapses but also to link the signaling molecules and receptors to efficiently act in response to certain extracellular stimuli. Mutations in these molecules may disrupt several different signaling pathways and result in wide range of cellular defects, which sometimes are not limited to ASD. In addition, couple autism-associated genes that have been shown to regulate synaptic vesicles also play roles in neurite outgrowth or synaptic plasticity thereby regulating the structural stability of neurons. An interesting direction of investigation is whether the regulation of synaptic vesicles represents one of the key vulnerable cellular pathway that contributes to the alteration of neuronal structures in ASD.

Specific Syndromic Disorder Related Genes
=========================================

Several autism-related neurodevelopmental disorders, such as Fragile X, Rett, Angelman syndromes (AS), and tuberous sclerosis are caused by a highly penetrable mutation of a single gene, e.g., *FMR1* in Fragile X ([@B620]; [@B213]), *MECP2* in Rett ([@B10]), *UBE3A* in AS ([@B316]), and *TSC1/2* in tuberous sclerosis complex (TSC; [@B480]). In recent DMS-5 criteria, however, ASD condition has been separated out from these single gene related disorders. Interestingly, these molecules all have a major function in regulating gene expression or protein synthesis, which in turn widely affects the structural stability of neurons. Because of the comorbidity between ASD and these single gene related disorders, we also review the current understanding of these genes and discuss how alterations of these genes may impair the structural integrity of neurons.

FMRP
----

FMRP is a RNA-binding protein encoded by *FMR1* gene ([@B23]; [@B548]). Mutations of the *FMR1* gene in humans result in CGG repeat polymorphisms or in the deletion of FMRP protein contributing to Fragile X syndrome, the most common inherited form of intellectual disability ([@B620]; [@B213]). Interestingly, people with Fragile X syndrome often exhibit autistic behaviors and mutations of *FMR1* genes are also found in several cases of ASD ([@B625]; [@B186]; [@B499]; [@B242]; [@B99]; [@B676]). The absence of FMRP is associated with widespread morphological changes of dendrites and dendritic spines in different brain regions, including cortex ([@B131]; [@B642]; [@B282]; [@B224]; [@B430]; [@B204]; [@B205]; [@B388]; [@B78]; [@B141]; [@B452]; [@B486]; [@B53]; [@B11]; [@B645]), hippocampus ([@B71]; [@B530]; [@B17]; [@B228]; [@B344]; [@B11]), and cerebellum ([@B319]).

Upon mGluR-activation, the local translation of *Fmr1* in dendrite and dendritic spines is crucial for maintaining dendritic structure ([@B16]; [@B42]; [@B594]; [@B445]; [@B479]). The hyperactivation of mGluR5 signaling, as well as the neuronal and behavioral deficits resulting from FMRP deficiency can be corrected by application of a mGluR5 antagonists ([@B42]; [@B41]; [@B594]; [@B167]; [@B484]; [@B648]; [@B24]; [@B445]; [@B345]; [@B396], [@B395]; [@B501]; [@B363]; [@B479]). The activation of FMRP subsequently regulates the local synthesis of several other synaptic proteins, including AMPAR, CaMKII, and PSD95, which in turn modulates the activity-dependent dynamics and plasticity of dendritic spines ([@B405]; [@B412]; [@B298]; [@B277]). In addition, the Rac-PAK pathway is upregulated and coincides with the disruptive dendritic phenotype in the absence of FMRP ([@B340]; [@B245]; [@B105]; [@B66]). A rare deletion and several variants of cytoplasmic FMR1 interacting protein 1 (*CYFIP1*) are also found in cases of ASD further suggesting genes involved in the FMRP signaling pathway are prevalent risk factors ([@B606]; [@B338]; [@B587]; [@B631]; [@B636]). Interestingly, CYFIP1 mediates FMRP-dependent protein translation to regulate the dendritic complexity and the stability of dendritic spines ([@B417]; [@B154]; [@B457]). Overexpression of CYFIP1 results in an increase of dendritic branching and dendritic spine density ([@B434]). Thus, the understanding of the molecular mechanisms regulated by FMRP provides insights into how mutations of *FMR1* in ASD may affect neuronal function and contribute to autistic behaviors.

MECP2
-----

Methyl-CpG binding protein 2 (MECP2) is a transcriptional factor that has multiple functions in gene regulation ([@B389]; [@B415], [@B416]; [@B674]; [@B94]; [@B109]). Mutations of *MECP2* gene contribute to 90% of cases with Rett syndrome, which is a severe developmental disorder exhibiting autistic phenotypes ([@B10]; [@B535]; [@B605]). Interestingly, the *MECP2* duplication syndrome also exhibit phenotypes that resemble those with ASD ([@B491]; [@B466]; [@B364]). Mutations and CNVs of *MECP2*, including duplication of the gene, have been identified in people with ASD without the diagnoses of either Rett or *MECP2* duplication syndromes ([@B90]; [@B679]; [@B541]; [@B564]; [@B88]; [@B526]; [@B143]; [@B240]; [@B354]; [@B676]). Most studies on MECP2 function focus on the understanding of the etiology of Rett syndrome and the *MECP2* duplication syndrome. Upregulation or downregulation of MECP2 dramatically alters the dendritic and axonal architecture of neurons and significantly disrupts the connectivity of neuronal networks ([@B202]; [@B296]; [@B32]; [@B45]; [@B97]; [@B315]; [@B126]; [@B379]; [@B426]; [@B559]; [@B288]; [@B30]). Overexpression of BDNF appears to restore the dendritic defects in *Mecp2*-null condition suggesting a molecular mechanism regulated by MECP2 to maintain the structural stability of neurons ([@B686]; [@B333]; [@B208]). Synaptic plasticity is also regulated by the expression or the phosphorylation of MECP2 ([@B130]; [@B148]; [@B22]; [@B403]; [@B96]; [@B680]; [@B348]; [@B432]; [@B58]; [@B408], [@B409]; [@B487]; [@B684]; [@B158]; [@B160]; [@B151]). Whether a similar mechanism to Rett or *MECP2* duplication syndromes is altered in ASD individuals with *MECP2* mutations needs to be further evaluated.

UBE3A
-----

*UBE3A* gene is a paternally imprinted gene located at human chromosome 15 and encodes a member of the E3 ubiquitin ligase proteins ([@B265]; [@B5]). Because *UBE3A* is selectively imprinted in mature neurons, epigenetic regulation of *UBE3A* has been associated with several neurodevelopmental disorders ([@B5]; [@B334]). Mutations resulting in loss-of-function in the maternally expressed copy of *UBE3A* causes AS, a severe developmental disorder characterized by delayed development, intellectual disability, severe speech impairment, and ataxia ([@B316]). Maternal duplication of *UBE3A* results in Dup15q syndrome, a developmental disorder that has many similarities with AS but also exhibits several autistic traits ([@B136]; [@B639]; [@B256]; [@B550]; [@B598]; [@B3]; [@B214]). Coincidently, several genome-wide studies from individuals with autism identify *UBE3A* as an autism-risk gene ([@B433]; [@B219]; [@B526]; [@B303]; [@B93]; [@B279]; [@B677]). In addition to its function of ubiquitin ligase to catalyze the protein degradation step, UBE3A also can act as a transcriptional coactivator for the nuclear hormone receptor superfamily of transcription factors ([@B419]). UBE3A localizes both in the nucleus and cytosol, including dendrite and pre- and post-synaptic compartments in neurons to regulate dendrite and dendritic spine morphology ([@B166]; [@B601]). Although maternal deletion of *Ube3a* does not affect dendrite arborization in mouse brains, knockdown of UBE3A in cultured neurons results in defects of dendrite polarization in pyramidal neurons ([@B166]; [@B394]). Maternal-deficiency of *Ube3a* in mouse brain, however, shows defects in dendritic spine development in the cortex, hippocampus, and cerebellum ([@B166]; [@B308]). Furthermore, several neuronal substrates for UBE3A have been identified, including Arc ([@B225]), the Rho-GEF Pbl/ECT2 ([@B495]), Ephexin5 ([@B377]), and TSC2 ([@B683]). Their regulation by UBE3A provides molecular mechanisms to explain how synaptic integrity is maintained and how alteration of this interaction contributes in part to neuronal phenotypes in neurodevelopmental disorders. In addition, a recent study demonstrates that a PKA phosphorylation-defective mutation on *UBE3A* found in an individual with autism resulted in an increase of dendritic spine density ([@B667]).

TSC1/TSC2
---------

*TSC1* and *TSC2* genes encode protein harmartin and tuberin, respectively, and they bind and function together ([@B183]; [@B608]; [@B609]). Mutations of *TSC1* or *TSC2* genes cause an autosomal dominant disorder TSC, which is characterized by hamartomas in various organs ([@B480]; [@B140]). Some patients with TSC exhibit several neurological problems including autism ([@B549]; [@B64]). Similarly, mutations of *TSC1* or *TSC2* are also found in several ASD cases ([@B549]; [@B533]; [@B526]; [@B303]; [@B443]; [@B323]; [@B72]; [@B587]; [@B327]). TSC1/2 act upstream as to suppress the mammalian target of rapamycin (mTOR) pathway and mTOR inhibitors have been promising therapeutic agents to ameliorate some symptoms in TSC ([@B207]; [@B391]; [@B145]). One of the mTOR inhibitors, rapamycin, has also been shown to correct the autistic-like synaptic pruning deficits in *Tsc2^+/-^* mice ([@B575]). In addition to the mTOR pathway being the key downstream target for TSC1/2, LIMK-cofilin pathway is altered upon deletion of TSC1 or TSC2 and enlargement of somas and dendritic spines are observed ([@B581]). The *Tsc2* mutations result in a loss of Purkinje cells and *Tsc1* mutant mice have increased dendritic spine density, which correlates with cerebellar dysfunction and several autistic-like behaviors in animals ([@B592]; [@B496]). TSC1/2 also negatively regulates neurite and axonal outgrowth ([@B191]; [@B116]). It has yet to be determined whether *TSC1/2* mutations in ASD correlate with perturbations of neuronal structures.

Perspectives
============

Diagnosis of ASD cases has risen dramatically in recent years. The increased awareness of the symptoms and the broader definition of the spectrum may be major contributing factors for the rising number of ASD cases. Thus, there is an increased interest on understanding the etiologies of ASD. It is widely accepted that the genetic component plays a major role in ASD, however, except for the direct inheritance of some syndromic conditions, it is difficult to identify risk factors for autism. It is possible due to the low sample size and the high heterogeneity of genetic variances to have sufficient statistical power to make conclusive correlations ([@B215]). Among those autism-risk genes identified to date, some of the autism associations are due to *de novo* mutations, and some are familial variants (**Table [4](#T4){ref-type="table"}**). Whether the inheritance pattern exhibits a risk factor is still not clear, however, the diverse gene mutations found in different individuals with autism suggest that instead of focusing on the genes *per se*, identifying the vulnerable pathways that these genes regulate may provide better clues toward understanding the contributing cellular and molecular changes that reserve in the autism phenotypes. The cellular defects resulting from different combinations of gene mutations contribute to the diverse phenotypes observed in autism. The heterogeneity of symptoms in ASD further complicates the diagnosis and treatment. However, understanding how autism-associated genes function in the regulation of key cellular pathways will provide insights to how therapeutic intervention can be more targeted and efficient to treat affected individuals.

###### 

Inheritance pattern of autism-risk genes that regulate the structural stability of neurons.

  Functional category      *De novo* variants                                                                                           Familial variants
  ------------------------ ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytoskeletal regulator   *CTTNBP2, [ADNP]{.ul}, [SYNGAP1]{.ul}*                                                                       *[CTTNBP2]{.ul}, ADNP, SYNGAP1*
  Adhesion molecule        ***CDH10***, *CDH11, PCDH10, PCDH19, FAT1, CTNNA3, NRXN1-3, NLGN1*, ***NLGN2***, *NLGN3, CNTNAP2, CNTN4-6*   ***CDH2, CDH8***, ***CDH9***, *CDH11*, ***PCDH9***, *PCDH10, PCDH19, FAT1, [CTNNA3]{.ul}, NRXN1, [NRXN2]{.ul}, NRXN3, NLGN1, NLGN3, [CNTNAP2]{.ul}*, ***CNTN3***, *[CNTN4]{.ul}, CNTN5-6*
  Surface receptor         ***GRIK4***, *NTRK3, [GRIN2B]{.ul}*                                                                          ***GRIK2***, *NTRK3, GRIN2B*
  Signaling molecule       *[DYRK1A]{.ul}, [CDKL5]{.ul}, PTEN*                                                                          *DYRK1A, CDKL5, PTEN*
  Synaptic molecule        *SHANK1-3, DLGAP2, STXBP5*                                                                                   *[SHANK1]{.ul}, SHANK2-3, [DLGAP2]{.ul}, [STXBP5]{.ul}*, ***PRICKLE1, CYFIP1***
  Syndromic molecule       *FMR1, MECP2, UBE3A, TSC2*                                                                                   *FMR1, MECP2, UBE3A*, ***TSC1****,TSC2*
                                                                                                                                        

This table shows whether autism-risk variants found in these genes are

de novo

mutations or familial variants. Most genes have

de novo

and familial variants, however, some of genes show a preferential inheritance pattern (underlined; label in bold if only one pattern is found).

Neuroanatomical studies of individuals with autism suggest a common disruption of neuronal structures with a decrease of dendrite arborization but an increase of dendritic spine density in select brain regions ([@B492]; [@B40]; [@B271]; [@B575]). This feature is distinct from other neurodevelopmental disorders, such as Rett or Fragile X syndromes, where the dendrite arbors and dendritic spine density are both downregulated ([@B328]). Intriguingly, dendrite arborization completes prior to dendritic spine formation during development. Although it has been proposed that the pruning mechanism of dendritic spines is defective in ASD ([@B198]), it is also plausible that the increase of dendritic spine density may be a compensation to re-establish the sufficient quantity of connections with fewer dendrite arbors. However, the precise spatial arborization of dendrites is critical for correct pre- and post-synaptic innervation when establishing the brain circuitry. The local increase of dendritic spine density may not be sufficient to compensate the effect from the loss of dendrite arbors, and may instead result in abnormal synaptic activity to disrupt normal neuronal function. This further emphasizes the importance of the establishment of structural integrity for neurons in order to provide proper brain function. In addition, the mechanisms of action of many current pharmacological agents for treating ASD affect normal neuronal function including the structural stability of neurons. With the early onset of ASD, the treatment often occurs at a very young age when the brain is still undergoing the period of development and maturation. As these pharmacological treatments may be beneficial to ameliorate some symptoms in ASD, the general brain development of these individuals may also be affected ([@B460]). Thus, more precise circuitry-specific therapeutic intervention is needed to reduce the unwanted effect to the developing brain. Understanding the genetic and cellular pathways affected in ASD should provide more selective candidates for developing targeted intervention.

Although the list of autism-associated genes that regulate neuronal structures is extensive, it stands out that several genes actually function in the same signaling pathways (**Table [5](#T5){ref-type="table"}**). For example, the mGluR5 pathway is disrupted when *Shank3* ([@B622]), *Fmr1* ([@B217]; [@B167]; [@B484]; [@B648]; [@B247]; [@B501]), *Ube3a* ([@B471]), or *Mecp2* ([@B684]) gene is altered. Application of mGluR5 antagonists has been shown to be promising to restore some phenotypes experimentally in neurons or animals with *Fmr1* mutants ([@B484]; [@B648]; [@B345]; [@B396], [@B395]; [@B501]; [@B479]). Whether targeting mGluR5 pathway can be clinically effective for ASD with mutations beyond *FMR1* will require further investigation. The mTOR pathway is defective when *Pten* ([@B286]; [@B329]; [@B685]; [@B485]), *Tsc1/2* ([@B207]; [@B391]; [@B145]), or *Mecp2* ([@B497]) gene is mutated. However, the mTOR pathway is upregulated in mice carrying defective gene products of *Pten. Tsc1/2*, or *Fmr1*, but downregulated in *Mecp2*-null mice. The mTOR inhibitor, rapamycin, has been shown to be effective to rescue some phenotypes caused by these mutations and has been used as a therapeutic agent to treat some of the autism symptoms ([@B391]; [@B177]; [@B145]). The alteration of IGF-1/GSK3β pathway is implicated in *Pten* ([@B329]), *Cdk5l* ([@B200]) or *Mecp2* ([@B283]) mutant animals. Inhibition of GSK3β or application of IGF-1 can rescue the dendritic phenotype in *Cdk5l* and *Mecp2* mutant mice ([@B590]; [@B199]; [@B159]). The mTOR pathway and the GSK3β pathway can be further linked together as they are both regulated by AKT. In addition, Rac1 activity is altered when *Elmo1* ([@B226]), *Cdk5l* ([@B106]), *Shank3* ([@B171]), or *Fmr1* ([@B340]; [@B105]; [@B66]) is mutated suggesting its crucial role to maintain the stability of neurons. The potential therapeutic approach targeting the Rac1 pathway to rescue the neuronal and behavioral phenotype in mutant animals is actively under investigation ([@B245]; [@B171]).

###### 

The common signaling pathways that are altered by mutations of autism-risk genes.

  Altered signaling pathway   Autism-risk gene involved      Available pharmacological agent
  --------------------------- ------------------------------ -------------------------------------------------------------
  mGluR5                      *SHANK3, FMR1, UBE3A, MECP2*   mGluR5 antagonists (e.g., fenobam, mavoglurant, CTEP, MPEP)
  PI3K/Akt/mTOR               *PTEN, MECP2, TSC1/2*          mTOR inhibitor (e.g., rapamycin)
  IGF-1/GSK3β                 *PTEN, CDK5L, MECP2*           IGF-1, GSK3β inhibitor (e.g., SB216763)
  Rac1                        *ELMO1, CDK5L, SHANK3, FMR1*   N/A
                                                             

Several pharmacological agents targeting these pathways are available and have successfully rescued the neuronal phenotype and function experimentally. References can be found in the text.

To date, several animal studies have tried to model the behavior phenotypes in autism, however, there remains a debate as to whether rodents can sufficiently recapitulate the complexities of the condition in human. The heterogeneity of genetic components also make it difficult to establish reliable animal models to describe the cellular and molecular mechanistic alterations in specific pathways. However, the studies on rodents can suggest which brain circuitry should be the area of interest for the corresponding behavior. iPSCs derived from ASD individuals appear to be an attractive model systems that allow researchers to directly investigate the interaction between the genetic contribution and the autism-relevant phenotypes. However, what is lacking in this system is a physiological relevant environment to correlate the behavior and the cellular phenotype. A recent emerging genetic editing technique, CRISPR/Cas9 ([@B292]), is a powerful tool to study the mechanistic questions and identify the potential therapeutic interventions. Unlike the traditional knock-in or knock-out technique, CRISPR/Cas9 can introduce genomic editing of several genes at once. Using CRISPR/Cas9 in iPSCs can potentially determine the genetic contribution to the cellular phenotypes and provide a mechanism to correct them. However, there is still room for improvement of the efficiency and precision before this technique can be reliably used in clinical applications. Combining animal studies, iPSC models, and gene editing techniques, it is now possible to perform more comprehensive translational research in order to better understand the etiologies of ASD and design more efficient and effective therapeutic interventions.
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